Ohio State Navbar

Fellowship Training Programs

Adult Congenital Heart Disease

In the US, there are approximately 1 million adults with congenital heart disease, with 20,000 new patients reaching adolescence each year. With early diagnosis in childhood and improved medical, surgical and ICU care, the number of adults will continue to rise. Despite improved survival to adulthood, many patients will continue to have problems with residual shunts, valvular heart disease, ventricular dysfunction, heart failure and arrhythmias. The risk of sudden death in adults with congenital heart disease is nearly 25-50 times greater than would be expected for their age. The Adolescent and Adult Congenital Heart Disease Program at Nationwide Children's Hospital and The Ohio State University Medical Center was created to meet the medical and surgical needs of this unique and complex population. The program is comprised of experts with an understanding of the natural history of congenital heart disease as well as the care after surgical or specialized transcatheter therapy.

This 5-year program includes 24 months clinical training at Nationwide Children's Hospital and 24 months clinical training at Ohio State as well as 12 months of research between both programs.  Upon successful completion, the trainee will have the ability to sit for both pediatric and adult boards as given by the ABIM.  Fellowship training and cardiovascular services in this fellowship include:

  • Medical and surgical evaluations
  • Advanced cardiac imaging
       Cardiovascular magnetic resonance
       Multidetector computed tomography
  • Cardiac catheterization and interventional procedures
       Balloon valvuloplasty and angioplasty: all cardiac valves, arteries and veins
       Transcatheter closure of intra and extracardiac shunts: ASDs, PFOs, VSDs, PDAs
       Stent therapy for vascular obstructions associated with congenital heart disease:
           PA  stenosis, coarctation of the aorta, venous obstruction
       Unique availability of new medical devices restricted to FDA sponsored clinical trials
  • Electrophysiologic procedures
       Diagnostic EP
       SVT/VT ablation
       Atrial fibrillation/flutter ablation associated with congenital heart disease
       Pacer/ICD implantation
  • Cardiopulmonary exercise testing
  • Heart failure/transplant evaluation
  • Pulmonary hypertension services
       Intravenous and subcutaneous prostacyclin therapy
       Oral endothelin blockers
       Clinical trials
  • Pregnancy and heart disease
       Medical, surgical and transcatheter therapies for cardiovascular high risk pregnancies
  • Comprehensive cardiothoracic surgical repair
       Valve repair/replacement
       Ross procedure: pulmonary autograft aortic valve replacement
       Surgical therapies of arrhythmias 
       Fontan revision
       Aortic valve-sparing aortic root replacement (Marfan syndrome)

For more information regarding the ACHD training program, please contact:

Curt J. Daniels, MD
Director, Adolscent and Adult Congenital Heart Disease Program
The Heart Center at Nationwide Children’s Hospital
Director, Pulmonary Hypertension Services, OSU
Office Children’s: 614-722-2530
Office OSU: 614-293-4967
Email: Curt.Daniels@osumc.edu

Timothy M. Hoffman, MD, FACC
Director, Pediatric Cardiology Fellowship Program, Nationwide Children's Hospital
Medical Director, Heart Transplant and Heart Failure Program, Nationwide Children’s Hospital
Office: 614-722-2530
Email: timothy.hoffman@NationwideChildrens.org